Cybin Inc (CYBN) Renews $35M At-The-Market Equity Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks weigh on markets
- Oil jumps around 5% to two-week high after Trump warns of more attacks on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
August 23, 2023 9:37 PM EDTTORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) (Cybin or the Company), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today that it has renewed its previously established at-the-market equity program (the ATM Program) that allows Cybin to issue and sell up to US$35,000,000 of common shares (Shares) in the capital of the Company from treasury to the public, from time to time, through the Agents (as defined below). All Shares sold under the... More
